During these past few months, the push to discover effective treatments and vaccines against COVID-19 has largely overshadowed another vitally important aspect of drug development: drug pricing. Let’s take a look at a recent example from pharma giant Gilead, who recently announced the pricing for its promising COVID-19 treatment remdesivir.

In direct support of the fight against the novel coronavirus and the world's effort to understand more about the mechanisms of the COVID-19 disease, we're proud to announce the arrival of our SARS-CoV-2 Neutralizing Antibody.

Over these past few months, we here at ABclonal have been working diligently to continue supplying necessary reagents to researchers, clinicians, and companies worldwide to facilitate their efforts during the COVID-19 pandemic. In direct support of that goal, we’re proud to introduce our new, comprehensive line of SARS-CoV-2 ELISA kits.

On a bit of a lighter note this week, let’s take a dive into the origins of the beloved Guinea pig and their often overlooked role in the development of some major breakthroughs in the field of medical research.

As we’ve seen over these past few months, a SARS-CoV-2 infection can result in widely different manifestations and severities in the subsequent course of the disease it causes, COVID-19. Many of those infected by SARS-CoV-2 experience a mild to severe illness, with symptoms that include fever, shortness of breath, cough, and fatigue that appear roughly 2-14 days after exposure to the virus. On the other hand, some individuals infected with the virus will remain asymptomatic. 

With troves of information and developments coming out daily from the various companies and researchers developing vaccines and potential treatments for COVID-19, it can certainly feel overwhelming to keep track of everything. This compilation of information should help you catch up on, and navigate recent developments in the fight against COVID-19.